美国动物再生医学市场：市场规模、份额和趋势分析（按产品、动物类型、应用和最终用途划分），细分市场预测（2025-2033 年）

市场规模与趋势：

据估计，2024 年美国兽医再生医学市场价值为 1.0807 亿美元，预计到 2033 年将达到 2.8168 亿美元，2025 年至 2033 年的复合年增长率为 11.5%。

这个市场的主要驱动力是伴侣动物慢性疾病（如关节炎、骨关节炎和肌腱损伤）的日益普遍，这增加了对先进治疗方案的需求。宠物饲养率的上升以及饲主愿意在专业兽医护理上投入更多资金，进一步推动了干细胞疗法和组织工程等再生医学方法的应用。此外，兽医生物技术公司不断取得的技术进步和持续的投资，正在加速创新，并扩大再生医学产品在国内的供应。

临床研究透过为先进疗法提供科学检验和监管认可，在推动美国兽医再生医学市场成长方面发挥着至关重要的作用。例如，根据美国食品药物管理局（FDA）称，美国，特别是纽约州，正在进行自体脂肪或骨髓间间质干细胞治疗犬类肌肉骨骼和神经系统疾病的临床研究。这些研究不仅证明了再生疗法治疗关节炎和肌腱损伤等疾病的安全性和有效性，而且增强了兽医和饲主的信心，并加速了其广泛应用。此外，积极的临床结果能够促进监管机构的支持，加强产业合作，并吸引生技公司的投资，从而进一步强化创新管道。透过将前沿研究转化为实际的兽医应用，这些临床试验显着促进了美国国内兽医再生医学市场的接受度、商业化和长期成长。

此外，兽医研究院校和提供再生医学服务的机构的存在，极大地促进了美国兽医再生医学市场的发展，它们充当了创新、培训和服务提供的中心。例如，田纳西大学农业研究所提供先进的服务，例如分离和扩增犬骨髓间质间质干细胞，以及製备用于治疗性注射的干细胞。这些机构不仅支持临床应用，也促进研发，进而推动再生技术在兽医学领域的快速应用。透过提供专业服务和专业知识，它们提高了兽医和饲主获得再生医学服务的便利性，增强了人们对先进疗法的信任，并提高了大众对再生疗法的认知。此外，这些中心也作为与生物技术公司和监管机构合作的枢纽，最终促进再生医学在美国兽医学界的商业化和普及。

目录

第一章 分析方法和范围

第二章执行摘要

第三章美国动物再生医学市场：驱动因素、趋势与范围

• 市场联动展望
  • 母市场
  • 子公司市场
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
  • 市场机会分析
  • 市场问题分析
• 美国动物再生医学市场：分析工具
  • 产业分析：波特五力分析
  • PESTEL 分析
• 定价分析
• 法律规范
• 主要国家主要品种动物数量估计（2021-2024 年）

第四章：美国动物再生医学市场：依产品分類的估算与趋势分析

• 细分仪表板
• 美国动物再生医学市场：按产品分類的变化分析
• 美国动物再生医学市场规模及产品趋势分析（2021-2033）
• 干细胞
• 其他的

第五章美国动物再生医学市场：按动物类型分類的估算与趋势分析

• 细分仪表板
• 美国动物再生医学市场：按动物类型分類的变化分析
• 美国动物再生医学市场规模及趋势分析（按动物类型划分）（2021-2033 年）
• 小动物
• 大型动物

第六章：美国动物再生医学市场：按应用分類的估算与趋势分析

• 细分仪表板
• 美国动物再生医学市场：按应用领域分類的趋势分析
• 美国动物再生医学市场规模与应用趋势分析（2021-2033）
• 整形外科
  • 创伤/创伤护理
• 其他的

第七章：美国动物再生医学市场：依最终用途分類的估算与趋势分析

• 细分仪表板
• 美国动物再生医学市场：依最终用途分類的变化分析
• 美国动物再生医学市场规模及趋势分析（按最终用途划分）（2021-2033 年）
  • 动物诊所和医院
  • 兽医研究所

第八章 竞争情势

• 市场参与企业分类
• 企业市场分析/热力图分析
• 公司简介
  • Boehringer Ingelheim International GmbH
  • Zoetis
  • Dechra Pharmaceuticals PLC
  • Equine Amnio Solutions
  • VetStem, Inc
  • Hilltop Bio
  • Equi-Stem LLC
  • Ardent Equine
  • Pronoia Biotech
  • AniCell BioTech
• 策略规划
  • 企业合併（M&A）
  • 商业伙伴关係与合作
  • 产品/服务发布
  • 其他的
• 其他主要企业名单

Market Size & Trends:

The U.S. veterinary regenerative medicine market size was estimated at USD 108.07 million in 2024 and is projected to reach at USD 281.68 million by 2033, growing at a CAGR of 11.5% from 2025 to 2033. The market is primarily driven by the growing prevalence of chronic conditions such as arthritis, osteoarthritis, and tendon injuries in companion animals, which is increasing the demand for advanced therapeutic solutions. Rising pet ownership and the willingness of owners to spend more on specialized veterinary care have further fueled the adoption of regenerative approaches such as stem cell therapy and tissue engineering. In addition, continuous technological advancements and rising investments by veterinary biotechnology companies are accelerating innovation and expanding the availability of regenerative medicine products in the country.

Clinical studies play a pivotal role in driving the growth of the U.S. veterinary regenerative medicine market by providing scientific validation and regulatory credibility to advanced therapies. For instance, according to the FDA, clinical studies on autologous adipose- or bone marrow-derived mesenchymal stem cells for canine musculoskeletal and nervous system diseases are being conducted in the U.S., specifically in New York. Such studies not only demonstrate the safety and efficacy of regenerative therapies in treating conditions such as arthritis and tendon injuries but also build confidence among veterinarians and pet owners, thereby accelerating adoption. Moreover, positive clinical outcomes encourage regulatory support, foster industry collaborations, and attract investments from biotechnology companies, further strengthening innovation pipelines. By translating cutting-edge research into practical veterinary applications, these clinical trials significantly contribute to expanding the acceptance, commercialization, and long-term growth of the veterinary regenerative medicine market in the country.

Moreover, the presence of veterinary research colleges and institutes offering regenerative medicine services significantly drives the growth of the U.S. veterinary regenerative medicine market by serving as centers of innovation, training, and service delivery. For example, the University of Tennessee Institute of Agriculture provides advanced services such as isolation and expansion of bone marrow-derived mesenchymal stem cells in dogs, and preparation of these stem cells for therapeutic injections. Such institutions not only support clinical applications but also promote research and development, enabling faster translation of regenerative techniques into veterinary practice. By offering specialized services and expertise, they increase accessibility for veterinarians and pet owners, build trust in advanced treatments, and enhance awareness of regenerative therapies. Furthermore, these centers act as hubs for collaborations with biotechnology firms and regulatory bodies, ultimately expanding the commercialization and acceptance of regenerative medicine across the U.S. veterinary healthcare landscape.

U.S. Veterinary Regenerative Medicine Market Report Segmentation

This report forecasts revenue growth provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. veterinary regenerative medicine market report based on product, animal type, application, end-use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Stem Cells
  • Others
• Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Animals
  • Large Animals
• Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Orthopedics
  • Trauma/Wound Care
  • Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Veterinary Clinics & Hospitals
  • Veterinary Research Institutes

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
  • 1.3.5. Details of Primary Research
  • 1.3.6. Data analysis model
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Regenerative Medicine Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of orthopedic disorders in pets
    • 3.2.1.2. Rising pet expenditure and pet humanization
    • 3.2.1.3. Strategic initiatives by key players
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of treatment.
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. U.S. Veterinary Regenerative Medicine Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Legal landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Social landscape
    • 3.3.2.5. Technological landscape
    • 3.3.2.6. Environmental landscape
• 3.4. Pricing Analysis
• 3.5. Regulatory Framework
• 3.6. Estimated Animal Population by key Species, key countries, 2021 - 2024

Chapter 4. U.S. Veterinary Regenerative Medicine Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Veterinary Regenerative Medicine Market: Product Movement Analysis
• 4.3. U.S. Veterinary Regenerative Medicine Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Stem Cells
  • 4.4.1. Stem Cells Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
• 4.5. Others
  • 4.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 5. U.S. Veterinary Regenerative Medicine Market: Animal Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Veterinary Regenerative Medicine Market: Animal Type Movement Analysis
• 5.3. U.S. Veterinary Regenerative Medicine Market Size & Trend Analysis, by Animal Type, 2021 to 2033 (USD Million)
• 5.4. Small Animals
  • 5.4.1. Small Animals Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
• 5.5. Large Animals
  • 5.5.1. Large Animals Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 6. U.S. Veterinary Regenerative Medicine Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Veterinary Regenerative Medicine Market: Application Movement Analysis
• 6.3. U.S. Veterinary Regenerative Medicine Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Orthopedics
  • 6.4.1. Orthopedics Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
  • 6.4.2. Trauma/Wound Care
  • 6.4.3. Trauma/Wound Care Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
• 6.5. Others
  • 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 7. U.S. Veterinary Regenerative Medicine Market: By End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Veterinary Regenerative Medicine Market: By End Use Movement Analysis
• 7.3. U.S. Veterinary Regenerative Medicine Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.3.1. Veterinary Clinics & Hospitals
    • 7.3.1.1. Veterinary Clinics & Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
  • 7.3.2. Veterinary Research Institute
    • 7.3.2.1. Veterinary Research Institute Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Position Analysis/ Heat Map Analysis
• 8.3. Company Profiles
  • 8.3.1. Boehringer Ingelheim International GmbH
    • 8.3.1.1. Participant's Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Product/Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Zoetis
    • 8.3.2.1. Participant's Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Product/Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Dechra Pharmaceuticals PLC
    • 8.3.3.1. Participant's Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Product/Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Equine Amnio Solutions
    • 8.3.4.1. Participant's Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Product/Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. VetStem, Inc
    • 8.3.5.1. Participant's Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Product/Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Hilltop Bio
    • 8.3.6.1. Participant's Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product/Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Equi-Stem LLC
    • 8.3.7.1. Participant's Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product/Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Ardent Equine
    • 8.3.8.1. Participant's Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product/Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Pronoia Biotech
    • 8.3.9.1. Participant's Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product/Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. AniCell BioTech
    • 8.3.10.1. Participant's Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product/Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
• 8.4. Strategy Mapping
  • 8.4.1. Mergers & Acquisitions
  • 8.4.2. Partnerships & Collaborations
  • 8.4.3. Product/Service launch
  • 8.4.4. Others
• 8.5. List of other key players

List of Tables

• Table 1 List Of Secondary Sources
• Table 2 U.S. Veterinary Regenerative Medicine Market, By Product, 2021 - 2033 (USD Million)
• Table 3 U.S. Veterinary Regenerative Medicine Market, By Animal Type, 2021 - 2033 (USD Million)
• Table 4 U.S. Veterinary Regenerative Medicine Market, By Application, 2021 - 2033 (USD Million)
• Table 5 U.S. Veterinary Regenerative Medicine Market, By End Use, 2021 - 2033 (USD Million)
• Table 6 Company Overview
• Table 7 Product Benchmarking
• Table 8 Financial Performance
• Table 9 Strategic Initiatives

List of Figures

• Fig. 1 Market Segmentation
• Fig. 2 Market Research Process
• Fig. 3 Information Procurement
• Fig. 4 Primary Research Pattern
• Fig. 5 Market Research Approaches
• Fig. 6 Value Chain-Based Sizing & Forecasting
• Fig. 7 QFD Modelling For Market Share Assessment
• Fig. 8 Market Formulation & Validation
• Fig. 9 U.S. Veterinary Regenerative Medicine Market Revenue, 2021 - 2033 (USD Million)
• Fig. 10 U.S. Veterinary Regenerative Medicine Market Snapshot
• Fig. 11 U.S. Veterinary Regenerative Medicine Market Driver Impact
• Fig. 12 U.S. Veterinary Regenerative Medicine Market Restraint Impact
• Fig. 13 U.S. Veterinary Regenerative Medicine Product Key Takeaways (USD Million)
• Fig. 14 U.S. Veterinary Regenerative Medicine Market: Product, Market Share 2024 & 2033
• Fig. 15 Stem Cells Market, 2021 - 2033 (USD Million)
• Fig. 16 Others Market, 2021 - 2033 (USD Million)
• Fig. 17 U.S. Veterinary Regenerative Medicine Animal Type Key Takeaways (USD Million)
• Fig. 18 U.S. Veterinary Regenerative Medicine Market: Animal Type, Market Share 2024 & 2033
• Fig. 19 Small Animals Market, 2021 - 2033 (USD Million)
• Fig. 20 Large Animals Market, 2021 - 2033 (USD Million)
• Fig. 21 U.S. Veterinary Regenerative Medicine Application Key Takeaways (USD Million)
• Fig. 22 U.S. Veterinary Regenerative Medicine Market: Application, Market Share 2024 & 2033
• Fig. 23 Orthopedic Market, 2021 - 2033 (USD Million)
• Fig. 24 Trauma/Wound Care Market, 2021 - 2033 (USD Million)
• Fig. 25 Others Market, 2021 - 2033 (USD Million)
• Fig. 26 U.S. Veterinary Regenerative Medicine Market By End Use: Key Takeaways
• Fig. 27 U.S. Veterinary Regenerative Medicine Market By End Use, Market Share, 2024 & 2033
• Fig. 28 Veterinary Clinics & Hospitals Market, 2021 - 2033 (USD Million)
• Fig. 29 Veterinary Research Institutes Market, 2021 - 2033 (USD Million)
• Fig. 30 Market Participant Categorization
• Fig. 31 Market Share Of Key Market Players U.S. Veterinary Regenerative Medicine Market